Arbutus Biopharma (ABUS) Accumulated Depreciation (2010 - 2018)

Arbutus Biopharma has disclosed Accumulated Depreciation across 9 years of filings, most recently posting $6.9 million for Q4 2018.

• Accumulated Depreciation for Q4 2018 came in at $6.9 million, down 45.58% year-over-year; the trailing twelve-month figure through Dec 2018 was $6.9 million (down 45.58% YoY), and the FY2018 annual result was $6.9 million, down 45.58% from the prior year.
• Accumulated Depreciation came in at $6.9 million for Q4 2018 at Arbutus Biopharma, up from $6.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $13.3 million in Q1 2018 to a low of $5.9 million in Q2 2018.
• The 5-year median for Accumulated Depreciation is $10.6 million (2016), against an average of $10.4 million.
• Peak annual rise in Accumulated Depreciation reached 19.8% in 2018, while the deepest fall reached 48.92% in 2018.
• Arbutus Biopharma's Accumulated Depreciation stood at $11.2 million in 2014, then slipped by 13.13% to $9.7 million in 2015, then rose by 10.37% to $10.7 million in 2016, then increased by 18.0% to $12.7 million in 2017, then slumped by 45.58% to $6.9 million in 2018.
• The last three Accumulated Depreciation figures came in at $6.9 million (Q4 2018), $6.4 million (Q3 2018), and $5.9 million (Q2 2018), per Business Quant data.